NECLIFE.NS Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 май 2024 @ 12:59):

Stats
Объем за сегодня	311 284
Средний объем	1.43M
Рыночная капитализация	7.89B
EPS	INR0 ( 2024-02-13 )
Дата следующего отчета о доходах	( INR0 ) 2024-05-27
Last Dividend	INR0.0500 ( 2020-09-18 )
Next Dividend	INR0 ( N/A )
P/E	97.78
ATR14	INR0.169 (0.48%)

Объем Корреляция

Длинно: 0.02 (neutral)

Кратко: -0.67 (moderate negative)

Signal:(49.81) Neutral

Nectar Lifesciences Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Nectar Lifesciences Корреляция - Валюта/Сырье

0.71
( moderate )

0.77
( moderate )

0.51
( weak )

0.72
( moderate )

0.16
( neutral )

-0.78
( moderate negative )

Nectar Lifesciences Финансовые показатели

Annual	2022
Выручка:	INR15.24B
Валовая прибыль:	INR3.64B (23.91 %)
EPS:	INR-1.080

FY	2022
Выручка:	INR15.24B
Валовая прибыль:	INR3.64B (23.91 %)
EPS:	INR-1.080

FY	2022
Выручка:	INR16.69B
Валовая прибыль:	INR2.99B (17.94 %)
EPS:	INR1.120

FY	2021
Выручка:	INR15.43B
Валовая прибыль:	INR2.58B (16.69 %)
EPS:	INR-3.27

Financial Reports:

No articles found.

Nectar Lifesciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Nectar Lifesciences Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 1.879 - low (50.00%) | Divividend Growth Potential Score: 2.81 - No dividend growth expected in the near future

Information

First Dividend	INR0.100	2006-02-01
Last Dividend	INR0.0500	2020-09-18
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	INR1.900	--
Avg. Dividend % Per Year	0.05%	--
Score	1.38	--
Div. Sustainability Score	1.879
Div.Growth Potential Score	2.81
Div. Directional Score	2.34	--

Next Divdend (Est)
(2024-09-10)

INR0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

1.38

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.0500	0.19%
2019	INR0.0500	0.24%
2020	INR0.100	0.81%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
RVNL.NS	Dividend Knight	2023-09-20	Annually	6	3.08%
LSIL.NS	Dividend Junior	2023-07-17	Annually	3	0.23%
GEOJITFSL.NS	Dividend Knight	2023-06-30	Annually	20	2.79%
ARVIND.NS	Dividend Junior	2023-07-21	Sporadic	20	0.59%
THEMISMED.NS	Dividend Junior	2023-08-31	Sporadic	18	0.39%
ORIENTELEC.NS	Dividend Junior	2023-07-26	Semi-Annually	7	0.41%
IRFC.NS	Dividend Junior	2023-09-15	Annually	4	2.61%
CUB.NS	Dividend Junior	2023-08-11	Annually	23	0.35%
SHRADHA.NS	Dividend Junior	2023-07-06	Sporadic	6	0.99%
MAPMYINDIA.NS	Dividend Junior	2023-08-25	Annually	3	0.13%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00493	1.500	9.90	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.00754	1.500	-1.027	-1.541	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	1.093	1.000	-0.706	-0.706	[3 - 30]
operatingCashFlowPerShareTTM	5.43	2.00	8.19	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.43	2.00	7.29	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.251	1.000	9.14	9.14	[0.2 - 0.8]
operatingProfitMarginTTM	0.0553	1.000	-0.893	-0.893	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				1.879

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	96.23	1.000	0.381	0	[1 - 100]
returnOnEquityTTM	0.00754	2.50	-0.660	-1.541	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.43	2.00	8.19	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	5.43	2.00	8.19	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.717	1.500	8.55	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0746	1.000	-0.635	0	[0.1 - 0.5]
Total Score				2.81

Nectar Lifesciences

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.